Novartis Pharmaceuticals Corp. v. Handa Neuroscience, LLC et al.

Case Overview and Background

Parties and the accused product. Plaintiff Novartis Pharmaceuticals Corp. is the global innovator behind GILENYA® (fingolimod) 0.5 mg capsules — the first FDA-approved oral sphingosine 1-phosphate receptor (S1PR) modulator for relapsing forms of multiple sclerosis (NDA No. 022527) — and is a Delaware corporation headquartered in East Hanover, New Jersey. Defendants are four affiliated Handa entities: Handa Pharmaceuticals, Inc., a Taiwanese corporation that serves as the group's parent, headquarters, and global R&D center; Handa Pharmaceuticals, LLC (Delaware, the group's generics business); Handa Pharma, Inc. (Delaware); and Handa Neuroscience, LLC (California, created July 2020), all sharing offices in San Jose, California. The suit, filed May 4, 2021 under the Hatch-Waxman and Declaratory Judgment Acts, arose from Handa Neuroscience's submission of NDA No. 214962 seeking approval of a 505(b)(2) version of GILENYA — fingolimod lauryl sulfate orally disintegrating tablets 0.5 mg (project "HND-020," marketed as TASCENSO ODT) — accompanied by a § 505(b)(2)(A)(iv) certification that the asserted patents were invalid, unenforceable, and/or not infringed. FDA granted the product tentative approval on October 18, 2021 (D. Del. D.I. 47, Mar. 1, 2022; RPX complaint excerpts).

Patents and procedural posture. Novartis asserted U.S. Patent No. 9,187,405 ("S1P Receptor Modulators for Treating Relapsing-Remitting Multiple Sclerosis," issued Nov. 17, 2015) — method-of-treatment claims directed to reducing, preventing, or alleviating RRMS relapses by orally administering 0.5 mg/day fingolimod "absent an immediately preceding loading dose regimen" — and U.S. Patent No. 10,543,179 ("Dosage Regimen of an S1P Receptor Modulator," issued Jan. 28, 2020), a follow-on method claim for treating RRMS with daily 0.5 mg fingolimod dosing, which Novartis deployed to extend dosing-regimen protection toward December 2027. The case was assigned to Judge Leonard P. Stark in the District of Delaware (Wilmington), who denied Handa's motion to dismiss or transfer to the Northern District of California in a March 1, 2022 opinion (D.I. 47), dismissing-with-prejudice the motion as to the three Delaware/Taiwan entities, denying transfer, and allowing venue-related discovery on whether Neuroscience was created to "manipulate venue"; the docket reflects later reassignment (a July 2022 letter was directed to Judge Maryellen Noreika regarding Handa's proposed '405 summary-judgment motion), and the case terminated under Judge Gregory B. Williams (GBW) after a Consent Judgment and Order of Injunction dated October 24, 2022 (case terminated Oct. 26, 2022 per DrugPatentWatch). Venue was central: Delaware was Novartis's preferred Hatch-Waxman forum where it had already won a final judgment on the '405 patent against ANDA filers (Novartis v. Accord Healthcare, C.A. No. 18-1043-KAJ, D.I. 780, Sept. 11, 2020), while Novartis filed a parallel "safety suit" in N.D. Cal. (5:21-cv-03397) two days after the Delaware complaint to protect the automatic 30-month stay regardless of the venue outcome; that California action was later transferred to Delaware as 1:22-cv-00352-GBW.

Why the case is notable and how it resolved. The case rode a landmark reversal in the fingolimod litigation ecosystem: on June 21, 2022, the Federal Circuit — on panel rehearing in Novartis v. Accord Healthcare, No. 2021-1070 — vacated its January 2022 affirmance and held the '405 claims invalid for inadequate written description of the negative limitation "absent an immediately preceding loading dose regimen," announcing that "silence is not disclosure" (Moore, C.J., and Hughes, J., majority; Linn, J., dissenting, after Judge O'Malley's retirement changed the panel). That decision reset Federal Circuit doctrine on negative claim limitations and § 112(a) written description, and it is why Handa sought leave to move for summary judgment on the '405 patent in this case in July 2022 — against the backdrop of the earlier favorable IPR Final Written Decision (Apotex v. Novartis, IPR2017-00854, PTAB July 11, 2018). The case never reached a merits ruling: on October 24–25, 2022, the parties settled, with a consent judgment under 21 U.S.C. § 355(c)(3)(C)(i)(II) in which Handa stipulated that the asserted claims were valid, enforceable, and infringed, took a license, and accepted an injunction barring U.S. sales until the agreed "Generic Entry Date," clearing the path to final FDA approval; Handa's Taiwan disclosure confirmed it would pay Novartis royalties on TASCENSO ODT net sales under confidential terms (paragraphfour.com consent judgment; Handa/Taiwan securities announcement, Oct. 25, 2022; Novartis press release, Sept. 21, 2022). The case is thus notable on three fronts: the doctrinal significance of the '405 invalidation; the venue-manipulation/In re Samsung analysis applied to a defendant's post-ANDA corporate restructuring in a Hatch-Waxman suit; and the strategic use of a parallel "safety suit" plus a consent-judgment settlement to preserve regulatory exclusivity and 30-month-stay leverage for a blockbuster MS franchise.

Sources: CourtListener docket 59881869 (D. Del. 1:21-cv-00645); Justia/Law.Justia D.I. 47 memorandum opinion (Mar. 1, 2022); RPX litigation-document excerpts of the complaint; Novartis v. Accord Healthcare, No. 2021-1070 (Fed. Cir. June 21, 2022) (panel rehearing); Novartis press release (Sept. 21, 2022); Handa Pharmaceuticals Taiwan securities announcement (Oct. 25, 2022); proposed Consent Judgment and Order of Injunction (paragraphfour.com, Oct. 24, 2022); DrugPatentWatch litigation docket (case terminated Oct. 26, 2022). Judge-assignment sequencing after Judge Stark's departure is only partially verified from public docket entries; the settlement papers bear the GBW caption.

Key Legal Developments & Outcome — Novartis Pharmaceuticals Corp. v. Handa Neuroscience, LLC et al., No. 1:21-cv-00645 (D. Del.)

Case snapshot

• Court / Case No.: U.S. District Court for the District of Delaware, No. 1:21-cv-00645 (originally before Judge Leonard P. Stark; later reassigned to Judge Maryellen Noreika and finally Judge Gregory B. Williams).
• Patents in suit: U.S. Patent Nos. 9,187,405 (the "'405 patent" — 0.5 mg daily fingolimod regimen for relapsing-remitting MS, no preceding loading dose) and 10,543,179 (the "'179 patent" — 0.5 mg fingolimod regimen with VZV-test/vaccination step).
• Product at issue: Handa's NDA No. 214962 for fingolimod lauryl sulfate orally disintegrating tablets, 0.5 mg ("TASCENSO ODT"/HND-020), a 505(b)(2) version of Novartis's GILENYA®.
• Disposition: Settled — confidential Settlement and License Agreement dated 2022-10-24; Consent Judgment and Order of Injunction entered; case terminated 2022-10-26.

---

Chronology

1. Filing & initial pleadings

• 2021-05-04 — Novartis filed its Hatch-Waxman complaint (D.I. 1) under 35 U.S.C. § 271(e)(2) and the Declaratory Judgment Act, alleging that Handa's NDA 214962 would infringe the '405 and '179 patents. (D.I. 4, Patent/Trademark Report to Commissioner, same day.)
• 2021-05-06 — Novartis filed a "safety suit" in the Northern District of California, Novartis Pharms. Corp. v. Handa Neuroscience, LLC, No. 5:21-03397 (N.D. Cal.), asserting the same two patents against the same four Handa entities to preserve the Hatch-Waxman 30-month stay regardless of the Delaware venue outcome. (Described in the Delaware court's 2022-03-01 opinion, D.I. 47.)
• 2021-05-20/21 — Parties stipulated to service of process and response time (D.I. 7; so ordered 5/21/21).
• 2021-05-27 — Novartis's pro hac vice counsel admitted (Jane M. Love, Ph.D., Robert W. Trenchard, Andrew P. Blythe, Christine L. Ranney — Gibson Dunn; D.I. 8).
• Answer/counterclaims: Handa's pleadings are not fully captured in the public docket excerpts I found, but the eventual Consent Judgment confirms Handa asserted counterclaims (invalidity/non-infringement), which were dismissed with prejudice at settlement. The specific answer docket entry and date are unverified in my sources.

2. Motion to dismiss / transfer (the principal early substantive motion)

• 2021-06-21 — Handa moved to dismiss under Rule 12(b)(6) and 12(b)(3) (improper venue as to California-based Handa Neuroscience) and, alternatively, to transfer to the Northern District of California under 28 U.S.C. §§ 1404(a)/1406(a) (D.I. 9; opening brief D.I. 10 sealed, redacted D.I. 12; briefing schedule D.I. 13).
• Briefing included Novartis's opposition (D.I. 16), Handa's reply (D.I. 27), a sur-reply (D.I. 29), and multiple supplemental-authority letters (D.I. 35–37, 39–40, 42–43, 45–46). Argument was heard by teleconference on 2022-01-24 (Tr. D.I. 44).
• 2022-03-01 — Memorandum Opinion (D.I. 47) and Order (D.I. 48), Judge Stark:
  • Denied with prejudice the motion as to Handa Pharmaceuticals, Inc., Handa Pharma, Inc., and Handa Pharmaceuticals, LLC, and denied transfer;
  • Denied without prejudice the venue challenge as to Handa Neuroscience, to be renewed after venue-related discovery;
  • Granted Novartis's sur-reply motion and directed the parties to propose a schedule "proceed[ing] to discovery and toward trial simultaneously with any venue-related discovery."
  • The opinion engaged Novartis's alter-ego/veil-piercing theory (based on forensic-accountant Kenneth Mathieu's declaration) and noted Novartis's accusation that Handa created the California entity to "achieve inconsistent results with respect to the '405 patent" after Novartis had successfully litigated that patent in Delaware (the coordinated HEC Pharm case, No. 1:20-cv-00133).
• Judge reassignments: The case was originally before Judge Stark (LPS); by July 2022 it was before Judge Maryellen Noreika (MN) (see the 7/27/2022 order signed by Noreika); by September–October 2022 it was before Judge Gregory B. Williams (GBW), who was coordinating it with the related HEC case, No. 1:20-cv-00133 (docket references to "1:21-cv-00645-GBW" and joint orders with 20-133).

3. The '405 invalidation and Handa's dispositive motions (June–August 2022)

This is the pivotal strategic development in the case:

• 2022-01-03 — In the parallel Novartis v. Accord Healthcare/HEC Pharm appeal, the Federal Circuit originally affirmed the Delaware bench-trial ruling that the '405 claims were not invalid for lack of written description of the "absent an immediately preceding loading dose regimen" negative limitation, Novartis Pharms. Corp. v. Accord Healthcare, Inc., 21 F.4th 1362 (Fed. Cir. 2022) (O'Malley, Linn; Moore, C.J., dissenting).
• 2022-06-21 — On panel rehearing (with a reconstituted panel: Moore, C.J., and Hughes in the majority; Linn, J., dissenting), the Federal Circuit vacated its prior decision and reversed, holding claims 1–6 of the '405 patent invalid for inadequate written description — "[s]ilence is generally not disclosure" — because the specification nowhere disclosed the absence of a loading dose. Novartis Pharms. Corp. v. Accord Healthcare, Inc., 38 F.4th 1013 (Fed. Cir. 2022).
• 2022-06-28 — Handa wrote to Judge Noreika requesting leave to file a summary judgment motion as to the '405 patent (based on the June 21 Federal Circuit ruling).
• July 2022 — Handa filed a motion for judgment on the pleadings and, after the court's initial response, a Motion for Reargument of Handa's Motion for Judgment on the Pleadings (D.I. 78); Novartis filed a response to the reargument motion (D.I. ~80). No ruling on these motions appears in the public record before settlement — they were rendered moot by the 10/24/2022 settlement. (Exact docket dates/numbers of the initial JOP motion are unverified.)
• The mandate saga continued in the HEC case, which affected the Handa case's trajectory: the Federal Circuit denied a stay of mandate (2022-09-27); Chief Justice Roberts stayed the mandate on 2022-09-29; the Supreme Court vacated the stay on 2022-10-13 (No. 22A272); the Federal Circuit mandate issued ~2022-10-19 (letter to Judge Williams, D.I. 213 in 20-133).

4. Claim construction (Markman)

• 2022-07-26 — The parties filed a Joint Claim Construction Chart (D.I. 114 in 21-645; D.I. 152 in 20-133) after extensions (stipulations extending to 7/25 and 7/26).
• 2022-07-27 — Judge Noreika ordered the claim construction hearing narrowed to no more than ten disputed terms, denied argument/decision on the remaining terms at the Markman stage, and permitted the parties to re-brief unaddressed terms in connection with dispositive motions (Order re D.I. 114/152).
• September–October 2022 — Further oral orders (D.I. 175, 179, ~9/22 and 9/29/2022) extended the deadline for an amended joint claim construction chart to 10/10/2022, and the claim construction hearing was set for 2022-10-06 (with Handa's motion for leave to amend and an expert-witness dispute to be heard in conjunction). No substantive Markman opinion issued — the hearing and chart process were superseded by the settlement.

5. Discovery milestones of strategic significance

• 2021-07-13 — Novartis served its first set of document requests and a subpoena (D.I. 13, notice of service).
• 2022-01-24 — Venue hearing (above); venue-related discovery ran alongside merits discovery per the 3/1/2022 order.
• 2022-05-17 — Novartis served responses to Handa's invalidity contentions on both patents (D.I. 75).
• June–July 2022 — The parties exchanged Final Infringement Contentions (Novartis) and Final Invalidity Contentions (Handa), followed by Novartis's responses to the final invalidity contentions (7/18/2022, D.I. 75 area). Handa served a second set of RFPs (Nos. 112–121).
• June–July 2022 — Depositions of fact witnesses including Lieselotte Bloss (Novartis notice, June 2022) and Li Qiao (7/20/2022); Novartis noticed a Rule 30(b)(6) deposition of the Handa entities (7/28/2022, sealed); a subpoena dispute involving non-party Bracken Data, Inc. was resolved by stipulation extending its objection deadline to 6/8/2022.
• August–October 2022 — Expert discovery was active, including a dispute over Novartis's designation of Dr. Joseph Berger as an expert (also litigated in the coordinated HEC case), and Handa's motion for leave to amend (likely to add a written-description invalidity defense following the June 2022 Federal Circuit decision). A discovery conference was scheduled for 10/28/2022 — after the settlement was signed.

6. Trial / post-trial events

• No trial occurred. The case settled during expert discovery and after claim-construction briefing but before the 10/6/2022 Markman hearing and the scheduled 10/28/2022 discovery conference. No jury demand was made (per docket metadata), and there are no verdict, JMOL, new-trial, or fee proceedings.

7. Settlement and final disposition

• 2022-10-24 — The parties executed a confidential Settlement and License Agreement (announced by Handa's Taiwan parent, Handa Pharmaceuticals, Inc. (TPEx: 6620), in a 2022-10-25 stock-exchange filing). Terms, per Handa's public filing: Novartis agreed to withdraw all related suits and terminate the litigation; Handa agreed to pay Novartis royalties on a percentage of TASCENSO ODT net sales under specified conditions (details confidential); both sides released all claims arising from the dispute. Handa also stated it would convert its FDA Tentative Approval (received 2021-10-18) to Final Approval and launch, consistent with its existing U.S. commercialization agreement with Cycle Pharmaceuticals.
• 2022-10-24 (proposed) / 2022-10-26 (entered) — The court entered a Consent Judgment and Order of Injunction. Key terms (from the proposed order):
  • Handa stipulated that all asserted claims of the '405 and '179 patents are valid and enforceable, and that the NDA 214962 product infringes all asserted claims;
  • Judgment entered that use of the accused product would infringe, with no extant cause of action by virtue of the license;
  • The judgment constitutes a consent decree under 21 U.S.C. § 355(c)(3)(C)(i)(II), permitting FDA Final Approval of NDA 214962 upon entry;
  • All claims and counterclaims dismissed with prejudice; the court retained jurisdiction over the Settlement Agreement;
  • Handa and affiliates enjoined from selling the accused product before the contractual "Generic Entry Date"; each party bears its own costs and fees; both parties waived appeal.
• 2022-10-26 — Case terminated (per docket metadata; DrugPatentWatch lists "Date Terminated 2022-10-26").
• N.D. Cal. "safety suit" (5:21-03397): Consistent with Handa's announcement that Novartis would "withdraw all related suits," the California action was part of the global settlement, but I could not verify its dismissal entry/date from available sources.

8. Parallel proceedings — Federal Circuit, Supreme Court, PTAB

• No PTAB IPR/PGR on the '405 or '179 patents by Handa surfaced in my searches; the validity fight here was litigated in court, not at the PTAB. The controlling parallel proceeding was the coordinated Delaware/Federal Circuit Accord/HEC litigation (No. 1:20-cv-00133 (D. Del.); No. 2021-1070 (Fed. Cir.)):
  • 2022-01-03: CAFC affirmed validity (21 F.4th 1362).
  • 2022-06-21: CAFC on rehearing reversed, holding claims 1–6 of the '405 patent invalid (38 F.4th 1013) — the event that triggered Handa's JOP/SJ motions in this case.
  • 2022-09-29 / 10-13: Supreme Court (Chief Justice Roberts) briefly stayed, then vacated the stay of, the Federal Circuit's mandate; mandate issued ~2022-10-19.
  • Novartis petitioned for certiorari in the HEC case (petition dated 2023-01-18); the outcome of that cert petition is unverified.
• Related later litigation: Novartis filed a separate Delaware action against Handa entities, Novartis Pharms. Corp. v. Handa Neuroscience, LLC et al., No. 1:22-cv-00352 (D. Del., filed 2022-03-21), also involving the '405 patent (per the Stanford NPE litigation database) — evidently a separate case from the one here, not consolidated in the sources I reviewed.

---

Bottom line

This was a Hatch-Waxman ANDA suit that never reached trial or a merits ruling. Novartis won the venue battle (motion to dismiss/transfer denied with prejudice as to three Handa entities and as to transfer, 2022-03-01), but the case was overtaken by the Federal Circuit's 2022-06-21 invalidation of the '405 patent (on rehearing in the coordinated HEC case), which prompted Handa's judgment-on-the-pleadings/summary-judgment push and likely reset the parties' leverage. The litigation ended in a global confidential settlement on 2022-10-24, embodied in a Consent Judgment and Order of Injunction entered 2022-10-26, under which Handa stipulated to the validity/infringement of both patents, obtained a license, and was enjoined from launching TASCENSO ODT before the contractual Generic Entry Date, with the case terminated the same day.

Source-verification caveats: I relied on CourtListener docket excerpts, the D. Del. venue opinion (D.I. 47/48), the Federal Circuit decisions (21 F.4th 1362; 38 F.4th 1013), the proposed Consent Judgment (paragraphfour.com), Handa's Taiwanese regulatory filing (2022-10-25), and DrugPatentWatch case-termination metadata. Unverified items I flag explicitly: the exact docket number/date of Handa's answer and the initial judgment-on-the-pleadings motion, the formal disposition of the N.D. Cal. safety suit, and whether any IPR petitions were ever filed on these patents (none were identified).

Based on the available docket record, the plaintiff Novartis Pharmaceuticals Corp. was represented by two firms in this Hatch-Waxman case: McCarter & English, LLP as Delaware local counsel and Gibson, Dunn & Crutcher LLP as national/lead counsel (admitted pro hac vice). The identities below are drawn from the docket (D.I. 8 pro hac vice motion, D.I. 13/47 filings), the CourtListener docket feed, Unicourt's attorney listing, and the parties' October 24, 2022 proposed Consent Judgment and Order of Injunction.

Plaintiff's Counsel of Record

Delaware Local Counsel — McCarter & English, LLP (Wilmington, DE)

1. Daniel M. Silver — Lead Delaware local counsel

• Firm/office: McCarter & English, LLP, Renaissance Centre, 405 N. King Street, 8th Floor, Wilmington, DE 19801 (Bar No. 4758)
• Role: Principal Delaware attorney of record; signed the complaint-era stipulations, letters to the Court (e.g., D.I. 180, 181), and the October 2022 consent judgment.
• Experience: Longtime Novartis Hatch-Waxman counsel in Delaware; also appeared for Novartis in Novartis Pharm. Corp. v. Accord Healthcare (the parallel Gilenya '405 patent litigation) and numerous other ANDA cases (per Casetext and docket signatures).

2. Alexandra M. Joyce — Delaware local counsel

• Firm/office: McCarter & English, LLP, Wilmington, DE (Bar No. 6423)
• Role: Delaware counsel of record; listed as a plaintiff attorney on the docket (Unicourt) and signed multiple Novartis filings; co-signed a joint discovery letter with defense counsel in October 2022 (D.I. 182).
• Experience: Hatch-Waxman and complex IP litigator in Delaware; Chambers USA-ranked for Delaware IP; lead/Delaware counsel in cases including the ArcherDX v. Qiagen jury trial (~$4.7M verdict).

3. Benjamin A. Smyth — Delaware local counsel

• Firm/office: McCarter & English, LLP, Wilmington, DE (Bar No. 5528)
• Role: Appeared on the signature block of the October 24, 2022 proposed Consent Judgment and Order of Injunction as attorney for Novartis.
• Experience: McCarter & English IP litigator in Delaware (part of the firm's Novartis ANDA team).

National / Lead Counsel — Gibson, Dunn & Crutcher LLP (pro hac vice)

4. Jane M. Love, Ph.D. — Lead national counsel

• Firm/office: Gibson, Dunn & Crutcher LLP, 200 Park Avenue, New York, NY 10166
• Role: Lead counsel; admitted pro hac vice via D.I. 8 (filed and granted May 27, 2021); listed as "Of Counsel" on the 2022 consent judgment.
• Experience: Chair of Gibson Dunn's Life Sciences and IP Litigation practices; lead counsel for Novartis in the Gilenya ANDA litigations (including the Delaware action against 23 ANDA filers and the Accord/HEC '405 patent trials); three-time Law360 Life Sciences MVP (2017, 2019, 2021).

5. Robert W. Trenchard — Co-lead national counsel

• Firm/office: Gibson, Dunn & Crutcher LLP, New York, NY
• Role: Pro hac vice (D.I. 8); "Of Counsel" on the 2022 consent judgment.
• Experience: Gibson Dunn litigation partner; co-led the Gilenya district court and PTAB matters with Dr. Love, including the preliminary injunction against at-risk generic launches; Patexia top-100 Hatch-Waxman practitioner (2023).

6. Andrew P. Blythe — National counsel (of counsel)

• Firm/office: Gibson, Dunn & Crutcher LLP, 333 South Grand Avenue, Los Angeles, CA 90071
• Role: Pro hac vice (D.I. 8); "Of Counsel" on the 2022 consent judgment.
• Experience: Gibson Dunn IP litigator in the firm's LA office (part of the Novartis Gilenya enforcement team; also appears in the related Federal Circuit record in Appeal No. 2021-1070).

7. Christine L. Ranney — National counsel (pro hac vice)

• Firm/office: Gibson, Dunn & Crutcher LLP (office location not confirmed in the sources reviewed)
• Role: Admitted pro hac vice with Dr. Love, Mr. Trenchard, and Mr. Blythe via D.I. 8 (May 27, 2021).
• Experience: Part of the Gibson Dunn Novartis/Gilenya team, per the pro hac vice certification. Her specific office and docket activity after admission are not verified in the sources I found.

8. Paul E. Torchia — National counsel (of counsel)

• Firm/office: Gibson, Dunn & Crutcher LLP, 200 Park Avenue, New York, NY 10166
• Role: Appeared later in the case; listed as "Of Counsel" for Novartis on the October 24, 2022 consent judgment (not in the May 2021 pro hac vice motion).
• Experience: Gibson Dunn life-sciences IP partner in New York (per the consent judgment signature block).

Additional Notes

• In-house counsel: No Novartis in-house attorney appears on the public docket as counsel of record in the sources reviewed; representation was by outside firms only.
• No sealed appearances: Nothing in the docket suggests plaintiff's counsel appearances were sealed.
• Procedural update relevant to the earlier summary: The case did not end solely via summary judgment on the '405 patent. After the Federal Circuit's June 21, 2022 decision in Novartis v. Accord Healthcare (Appeal No. 2021-1070) invalidated the '405 patent claims, Judge Gregory B. Williams ordered the parties to stipulate to dismissal of the '405 claims (D.I. 176, Sept. 22, 2022), and Novartis sought a stay of the mandate (D.I. 177–180; the Supreme Court stayed the mandate on Sept. 29, 2022). The parties then settled: a proposed Consent Judgment and Order of Injunction (with stipulations of validity/infringement as to both patents) was filed October 24, 2022, and DrugPatentWatch lists the case as terminated on October 26, 2022.
• Caveats: The office location for Christine L. Ranney is unverified. Attorney roles (lead vs. of counsel) are inferred from signature blocks and firm materials rather than a formal court designation; docket designations in D. Del. typically list all counsel collectively.

Key sources: D.I. 8 (pro hac vice motion, 5/27/21); D.I. 47 (Memorandum Opinion, 3/1/22); CourtListener docket 59881869 (entries 176–182); Unicourt case summary (plaintiff attorneys: Joyce, Silver); proposed Consent Judgment and Order of Injunction dated 10/24/22 (paragraphfour.com PDF); Gibson Dunn attorney bios (Love; Trenchard); McCarter & English bio (Joyce); IPWatchdog (6/21/22) on the Federal Circuit '405 decision; DrugPatentWatch termination date.

I have a strong lead from the consent judgment. Let me verify the full attorney roster, including any pro hac vice appearances and later-filed appearances (e.g., Stamoulis).

The docket feed shows this case was coordinated with the HEC Pharm lead case (1:20-cv-00133-MN), where Stamoulis represents HEC (not Handa). Let me verify the initial appearances and pro hac vice motions for the Handa defendants, plus attorney backgrounds.

Counsel of Record for Defendants (Handa Neuroscience, LLC; Handa Pharma, Inc.; Handa Pharmaceuticals, Inc.; Handa Pharmaceuticals, LLC)

Novartis Pharmaceuticals Corp. v. Handa Neuroscience, LLC et al., No. 1:21-cv-00645 (D. Del.)

I was unable to access PACER directly; the roster below is reconstructed from the RECAP/CourtListener docket feed, the Court's March 1, 2022 venue opinion (D.I. 47), the pro hac vice entries, and the signed proposed Consent Judgment filed October 24, 2022 (available via paragraphfour.com). All five attorneys below appear on the case's filings of record; no other defendant-side attorneys appear in the docket entries I could verify.

Delaware (local) counsel — Phillips McLaughlin & Hall, P.A., Wilmington, DE

• John C. Phillips, Jr. (Bar No. 110) — Local counsel / attorney of record for all four Handa entities. Partner at Phillips McLaughlin & Hall; he is the signatory on the defendants' answer (D.I. 53, 3/14/2022), venue briefing, redacted letters, and the proposed Consent Judgment. He is a veteran Delaware patent litigator who regularly serves as Delaware local counsel in Hatch-Waxman/ANDA and pharmaceutical patent cases (e.g., the coordinated Novartis v. HEC Pharm matters in this district).
• David A. Bilson (Bar No. 4986) — Local counsel / attorney of record. Also of Phillips McLaughlin & Hall; he filed the defendants' March 14, 2022 motion for pro hac vice admission of the Husch Blackwell attorneys (D.I. 52) and has filed claim-construction and other papers for the Handa defendants in the coordinated proceedings.

Lead / national counsel (pro hac vice) — Husch Blackwell LLP

• Don J. Mizerk — Lead counsel (pro hac vice). Husch Blackwell, Chicago office. Admitted pro hac vice for all Handa defendants by order of Judge Maryellen Noreika on March 14, 2022 (D.I. 52; "Pro Hac Vice Attorney Don J. Mizerk for Handa Neuroscience, LLC added for electronic noticing"). Signed the October 2022 Consent Judgment as of counsel. Mizerk is a Husch Blackwell partner focused on IP/patent litigation, including pharmaceutical/ANDA disputes.
• Matthew M. Kamps — Lead counsel (pro hac vice). Husch Blackwell, Chicago office. Admitted pro hac vice on the same March 14, 2022 order (D.I. 52). He filed a declaration in support of the defendants' sur-reply claim construction brief in the related coordinated matter and is a Husch Blackwell patent-litigation associate/partner with Hatch-Waxman experience.
• Dustin L. Taylor — Of counsel (pro hac vice). Husch Blackwell, Denver office. Pro hac vice admission granted earlier, per the Court's January 14, 2022 order on the D.I. 32 motion ("SO ORDERED, re 32 MOTION for Pro Hac Vice Appearance of Attorney Dustin L. ..."). Listed as of counsel on the October 2022 Consent Judgment.

Important clarification on a name that may surface in the docket

• Stamatios Stamoulis (Stamoulis & Weinroth LLC, Wilmington) appears throughout the coordinated docket — but for HEC Pharm Co. and HEC Pharm USA Inc., the separate defendants in the lead case Novartis v. HEC Pharm, No. 1:20-cv-00133-MN, with which this case was consolidated for pretrial purposes under Judge Maryellen Noreika (case reassigned to MN in March 2022). Joint letters such as the August 2022 discovery-conference letter list Stamoulis alongside Phillips and Novartis's Alexandra Joyce precisely because the filings covered both coordinated cases. He is not counsel for the Handa defendants.

In-house counsel

• None identified. No in-house attorney for any Handa entity appears of record on the docket entries reviewed. The Taiwanese parent (Handa Pharmaceuticals, Inc.) disclosed the litigation in a May 6, 2021 Taiwanese stock-exchange filing (announcing retention of counsel), but no in-house lawyer was admitted in this action.

Procedural context / caveats

• The case was filed May 4, 2021 before Judge Leonard P. Stark, reassigned to Judge Gregory B. Williams, and then to Judge Maryellen Noreika (MN) in March 2022 for coordination with the HEC Pharm lead case. The '405 patent was invalidated by the Federal Circuit in June 2022, prompting the defendants' summary-judgment and reargument motions (the court denied Handa's reargument motion on Aug. 23, 2022).
• The action was resolved by settlement: a proposed Consent Judgment and Order of Injunction dated October 24, 2022 (signed by Phillips, Bilson, Mizerk, Kamps, and Taylor for the defendants) recites that Handa stipulated to validity/infringement of both the '405 and '179 patents, took a license under a confidential settlement, and waived appeal; DrugPatentWatch records the case terminated October 26, 2022.
• Filings regarding the settlement and license were largely sealed (many docket entries are marked SEALED or "REDACTED VERSION"), so I could not verify whether additional counsel appeared in connection with the settlement negotiation; the signed consent judgment reflects the five-attorney roster above.

Sources: CourtListener RECAP docket feed for 1:21-cv-00645 (entries 32, 52, 53, 130–151, 178–182); D.I. 47 Memorandum Opinion (Justia/CourtListener); Unicourt case summary; proposed Consent Judgment PDF (paragraphfour.com/dedc21cv0645CJ.pdf); DrugPatentWatch case summary (termination 10/26/2022).